Celcuity (NASDAQ:CELC) Sets New 52-Week High – Here’s What Happened

Shares of Celcuity, Inc. (NASDAQ:CELC) reached a new 52-week high during trading on Monday . The company traded as high as $102.15 and last traded at $101.8880, with a volume of 248158 shares. The stock had previously closed at $97.50.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. HC Wainwright reiterated a “neutral” rating and issued a $94.00 target price (up previously from $77.00) on shares of Celcuity in a report on Monday, November 17th. Guggenheim started coverage on Celcuity in a report on Monday, September 22nd. They issued a “buy” rating on the stock. Needham & Company LLC set a $95.00 price objective on Celcuity in a research note on Monday, October 20th. Leerink Partners increased their target price on shares of Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, July 28th. Finally, Stifel Nicolaus raised their price target on shares of Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $97.00.

Celcuity Stock Performance

The stock has a 50 day simple moving average of $65.17 and a 200 day simple moving average of $40.06. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The company has a market cap of $4.68 billion, a price-to-earnings ratio of -27.56 and a beta of 0.72.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.13. As a group, analysts predict that Celcuity, Inc. will post -2.62 EPS for the current year.

Insider Buying and Selling at Celcuity

In related news, Director Richard E. Buller sold 3,900 shares of the firm’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the sale, the director directly owned 7,260 shares of the company’s stock, valued at approximately $702,259.80. This trade represents a 34.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 15.77% of the company’s stock.

Hedge Funds Weigh In On Celcuity

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harvest Investment Services LLC acquired a new stake in shares of Celcuity during the third quarter valued at about $1,427,000. Voloridge Investment Management LLC acquired a new stake in Celcuity during the 3rd quarter valued at approximately $9,439,000. Verition Fund Management LLC purchased a new stake in Celcuity during the 3rd quarter worth approximately $4,012,000. Scientech Research LLC acquired a new position in shares of Celcuity in the 3rd quarter valued at approximately $777,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Celcuity during the 3rd quarter valued at approximately $329,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.